Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Office of Patient Advocacy

This article was originally published in The Gray Sheet

Executive Summary

Agency is considering creating an office that would interact with healthcare consumers and disease advocacy groups to inform Medicare and Medicaid policy decisions. The office would resemble FDA's Office of Special Health Issues, which responds to patients' questions on HIV/AIDS, cancer, diabetes therapies and clinical trial enrollment. In addition, OSHI aids policymaking for "special populations," a role CMS also may adopt...

You may also be interested in...



CMS-Supported Clinical Data Collection Worth The Cost – Tunis

CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 
UsernamePublicRestriction

Register

MT020421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel